Phân tích thực trạng sử dụng kháng sinh linezolid đường tiêm truyền tại Bệnh viện Trung ương Quân đội 108

Abstract

Objective: To analyze the current status of linezolid use at 108 Military Central Hospital. Subject and method: A retrospective study of DDDs per 100 bed-days over 5 years (from 2019 to 2023) and medical records of inpatients treated with linezolid from April 1, 2022 to March 31, 2023. Result: Linezolid consumption significantly increased during the study period (S = 1044, p<0.001). Over a year, 343 linezolid episodes corresponding to 336 inpatients were included. Linezolid used in empiric regimens (59.1%), within label-use for linezolid (66.2%). We recorded 153 cases (44.6%) of inappropriate indications, primarily due to unsatisfactory use as an alternative to vancomycin (34.6%) and bacterial pathogens not within linezolid's treatment scope (24.2%). We recorded 153 cases (44.6%) of inappropriate indications, primarily due to unsatisfactory use as an alternative to vancomycin (34.6%) and bacterial pathogens not within linezolid's treatment scope (24.2%). Thrombocytopenia was the most commonly reported adverse event (24.9%), and 101 patients experienced drug interactions contraindicated with linezolid. Conclusion: Linezolid consumption in 2019-2023 tends to increase, and a high proportion of patients use linezolid with antibiotic indications that are not completely appropriate. Early issuance of protocol for the use of linezolid is necessary because it is a reserve antibiotic, especially when antibiotic resistance to vancomycin is on the rise.